Xinvento is a biotechnology company developing novel therapeutic agents for congenital hyperinsulinism. Their approach targets the underlying pathophysiology of the disease to reduce excessive insulin secretion and mitigate hypoglycemia. Xinvento's proprietary molecule development aims to improve long-term health outcomes for patients with this rare endocrine disorder.
Funding
Funding not disclosed
Founders
Product
Problem
Congenital hyperinsulinism (CHI) is a rare disease causing persistent hypoglycemia due to excessive insulin secretion, leading to severe health risks for affected newborns and children. Current treatment options, largely unchanged for 50 years, often result in frequent hypoglycemic episodes and require intensive daily management, significantly impacting patient quality of life and caregiver burden.
Solution
Xinvento is a biotechnology company focused on developing novel therapeutic agents for congenital hyperinsulinism. Leveraging extensive research and scientific expertise, the company aims to create a more effective and accessible treatment that addresses the underlying pathophysiology of the disease. By targeting the over-secretion of insulin, Xinvento's approach seeks to reduce the incidence and severity of hypoglycemic events, thereby improving long-term health outcomes and enhancing the daily lives of patients and their families. The company is advancing its proprietary molecule development through preclinical studies with the goal of identifying clinical candidate molecules.
Target Audience
Xinvento's primary focus is on patients diagnosed with congenital hyperinsulinism and their families, as well as the medical professionals and researchers involved in the treatment and study of this rare endocrine disorder.
Features
- Development of proprietary molecules targeting the root cause of hyperinsulinism.
- Focus on reducing insulin over-secretion to mitigate hypoglycemia.
- Preclinical research program designed to identify and advance clinical candidate molecules.
- Expertise in rare disease drug development and pharmaceutical R&D.
- Commitment to improving patient quality of life through advanced therapeutic options.